AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Overview of a yearly tax planning approach for index fund losses, detailing steps to track opportunities, document losses, and optimize filings.
19,656 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
SpaceX headlines grab attention, but smart investors look for durable earnings growth in established aerospace player...
MicroStrategy announces a sweeping Digital Credit Capital Framework that reshapes how it funds Bitcoin purchases and ...
A federal judge granted Alibaba a temporary reprieve from the Defense Department lobbying ban as she weighs the compa...
Class-action settlements can bring real money to legitimate claimants, but fraudsters have tried to exploit the syste...
Bitcoin climbs past $64,000 as spot BTC ETF inflows resume, highlighting a price-driven rebound that may outpace inst...
A high-stakes pivot: the team behind ethereum's institutional privacy push launches EthSystems, a for-profit venture ...
Crypto traders increasingly rely on AI to sift signals and manage portfolios. This gpt-5.6 fable review: which guide ...
A cruise stock jumps as an activist investor takes a stake, signaling potential governance shifts. This article break...
Get a fresh, investor-focused look at hamilton (hg) 2025 earnings. We'll break down revenue engines, margins, and wha...
A noted market analyst warns that Strategy’s aggressive Bitcoin purchases echo dot-com-era speculation, risking a ste...
Institutional players are accelerating tokenization and on-chain strategies, even as many traditional investors lag b...